Back to my company list

New

Cambridge Cognition

The AI engine Fit Assessment

Beta

Cambridge Cognition develops digital health tools and cognitive assessments that are used in pharmaceutical R&D and clinical trials, including drug development, decentralized clinical trials, and real-world digital health data, and is trusted by leading pharmaceutical and biotech organisations.

Blurb

Cognitive assessment software for clinical trials, academic research and healthcare

HQ Location

Bottisham (United Kingdom)

Founded

2002

Employees

51 - 200

Total funding raised

$3.21M

Funding Status

Post-IPO Equity, $1.51M, August 28, 2025

Cambridge Cognition Plc (AIM: COG) is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. Our software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.



Our digital health products have been used for over 30 years in thousands of academic and industry clinical trials by the world's leading pharmaceutical and biotech companies, academic institutions and health organisations.